Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03881488 · OUTCOME

Maximum Serum Concentration (Cmax) of CTX-471

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies · Source last updated 2026-10-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
ng/mL
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours and 2 weeks after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.

What was measured

Calculated from plasma concentrations measured from samples collected at times shown below

Analysis population: Pharmacokinetic Analysis Set: all patients who received CTX-471 (and pembrolizumab in combination arms) and had at least 1 post-treatment measurement and no protocol deviations or events affecting the validity of the results

Groups in this outcome

CTX-471 Monotherapy 0.1 mg/kg

0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks

CTX-471 Monotherapy 0.3 mg/kg

0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks

CTX-471 Monotherapy 0.6 mg/kg

0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks

CTX-471 Monotherapy 1.2 mg/kg

1.2 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks

CTX-471 Combination 0.1 mg/kg

0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks

CTX-471 Combination 0.3 mg/kg

0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks

CTX-471 Combination 0.6 mg/kg

0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
CTX-471 Monotherapy 0.1 mg/kg3
CTX-471 Monotherapy 0.3 mg/kg13
CTX-471 Monotherapy 0.6 mg/kg13
CTX-471 Monotherapy 1.2 mg/kg6
CTX-471 Combination 0.1 mg/kg2
CTX-471 Combination 0.3 mg/kg3
CTX-471 Combination 0.6 mg/kg4

Reported measurements

Week 1 dose

Analysis denominator · Participants

GroupSource count
CTX-471 Monotherapy 0.1 mg/kg3
CTX-471 Monotherapy 0.3 mg/kg13
CTX-471 Monotherapy 0.6 mg/kg13
CTX-471 Monotherapy 1.2 mg/kg6
CTX-471 Combination 0.1 mg/kg2
CTX-471 Combination 0.3 mg/kg3
CTX-471 Combination 0.6 mg/kg4
Values in ng/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
CTX-471 Monotherapy 0.1 mg/kg1564.535.2Not reportedNot reportedNot reported
CTX-471 Monotherapy 0.3 mg/kg6308.452.9Not reportedNot reportedNot reported
CTX-471 Monotherapy 0.6 mg/kg11249.933.8Not reportedNot reportedNot reported
CTX-471 Monotherapy 1.2 mg/kg25403.430.2Not reportedNot reportedNot reported
CTX-471 Combination 0.1 mg/kgNANANot reportedNot reportedInsufficient data to calculate geometric mean and geometric coefficient of variation
CTX-471 Combination 0.3 mg/kg7612.24.2Not reportedNot reportedNot reported
CTX-471 Combination 0.6 mg/kg7152.2286.3Not reportedNot reportedNot reported
Week 9 dose (steady state)

Analysis denominator · Participants

GroupSource count
CTX-471 Monotherapy 0.1 mg/kg1
CTX-471 Monotherapy 0.3 mg/kg4
CTX-471 Monotherapy 0.6 mg/kg3
CTX-471 Monotherapy 1.2 mg/kg3
CTX-471 Combination 0.1 mg/kg0
CTX-471 Combination 0.3 mg/kg0
CTX-471 Combination 0.6 mg/kg0
Values in ng/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
CTX-471 Monotherapy 0.1 mg/kg2950.0NANot reportedNot reportedA geometric mean coefficient of variation cannot be calculated for data from only 1 participant.
CTX-471 Monotherapy 0.3 mg/kg9880.434.9Not reportedNot reportedNot reported
CTX-471 Monotherapy 0.6 mg/kg10998.717.6Not reportedNot reportedNot reported
CTX-471 Monotherapy 1.2 mg/kg25731.738.1Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        35.2
        value
        1564.5
      2. group Id
        OG001
        spread
        52.9
        value
        6308.4
      3. group Id
        OG002
        spread
        33.8
        value
        11249.9
      4. group Id
        OG003
        spread
        30.2
        value
        25403.4
      5. comment
        Insufficient data to calculate geometric mean and geometric coefficient of variation
        group Id
        OG004
        spread
        NA
        value
        NA
      6. group Id
        OG005
        spread
        4.2
        value
        7612.2
      7. group Id
        OG006
        spread
        286.3
        value
        7152.2
    denoms
    1. counts
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        13
      3. group Id
        OG002
        value
        13
      4. group Id
        OG003
        value
        6
      5. group Id
        OG004
        value
        2
      6. group Id
        OG005
        value
        3
      7. group Id
        OG006
        value
        4
      units
      Participants
    title
    Week 1 dose
  2. categories
    1. measurements
      1. comment
        A geometric mean coefficient of variation cannot be calculated for data from only 1 participant.
        group Id
        OG000
        spread
        NA
        value
        2950.0
      2. group Id
        OG001
        spread
        34.9
        value
        9880.4
      3. group Id
        OG002
        spread
        17.6
        value
        10998.7
      4. group Id
        OG003
        spread
        38.1
        value
        25731.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        4
      3. group Id
        OG002
        value
        3
      4. group Id
        OG003
        value
        3
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        0
      units
      Participants
    title
    Week 9 dose (steady state)
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      13
    3. group Id
      OG002
      value
      13
    4. group Id
      OG003
      value
      6
    5. group Id
      OG004
      value
      2
    6. group Id
      OG005
      value
      3
    7. group Id
      OG006
      value
      4
    units
    Participants
description
Calculated from plasma concentrations measured from samples collected at times shown below
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks
    id
    OG000
    title
    CTX-471 Monotherapy 0.1 mg/kg
  2. description
    0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks
    id
    OG001
    title
    CTX-471 Monotherapy 0.3 mg/kg
  3. description
    0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks
    id
    OG002
    title
    CTX-471 Monotherapy 0.6 mg/kg
  4. description
    1.2 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks
    id
    OG003
    title
    CTX-471 Monotherapy 1.2 mg/kg
  5. description
    0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks
    id
    OG004
    title
    CTX-471 Combination 0.1 mg/kg
  6. description
    0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks
    id
    OG005
    title
    CTX-471 Combination 0.3 mg/kg
  7. description
    0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks
    id
    OG006
    title
    CTX-471 Combination 0.6 mg/kg
param Type
GEOMETRIC_MEAN
population Description
Pharmacokinetic Analysis Set: all patients who received CTX-471 (and pembrolizumab in combination arms) and had at least 1 post-treatment measurement and no protocol deviations or events affecting the validity of the results
reporting Status
POSTED
time Frame
Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours and 2 weeks after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.
title
Maximum Serum Concentration (Cmax) of CTX-471
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice